-+ 0.00%
-+ 0.00%
-+ 0.00%

Immunome submits FDA NDA for varegacestat in adult desmoid tumors

PUBT·04/29/2026 11:30:51
Listen to the news
Immunome submits FDA NDA for varegacestat in adult desmoid tumors
  • Immunome submitted New Drug Application to U.S. FDA for varegacestat to treat adults with desmoid tumors.
  • NDA backed by Phase 3 RINGSIDE trial showing 84% reduction in risk of progression or death vs placebo (HR 0.16).
  • Trial reported confirmed objective response rate of 56% for varegacestat vs 9% for placebo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunome Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260429083050) on April 29, 2026, and is solely responsible for the information contained therein.